Octreotide capsules are designed to exhibit the effects of somatostatin, a naturally occurring hormone that reduces the production of GH by binding to receptors on specialised cells in the pituitary gland.

Because octreotide capsules were developed using our Transient Permeability Enhancer (TPE®) technology, they can be administered orally and absorbed into the bloodstream. This means octreotide capsules have the potential to serve as an alternative to the current standard-of-care injection therapy that is available for people living with acromegaly today. There are currently no approved oral formulations of octreotide.

The U.S. Food & Drug Administration (FDA) granted authorisation for MYCAPSSA® in September 2020. MYCAPSSA® is indicated as:

A somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

See MYCAPSSA.com for further information (US audiences only).

MYCAPSSA is currently not approved in the EU, but has been filed with the European Medicines Agency (EMA)

AMYT/ALL/007 August 2021